The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.

Acute Myeloid Leukemia (AML)

To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.

Pevonedistat

Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.

transplant

Azacitidine

Penn State Hershey Medical Center: Penn State Cancer Institute

Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML

A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia

Cumulative incidence of relapse at 2 years

Shin Mineishi

Professor and Director, Blood and Marrow Transplant Program

Milton S. Hershey Medical Center

Millennium Pharmaceuticals, Inc.

Takeda

bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity

Metastatic Triple Negative Breast Cancer

Safety Issues

Efficacy

-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .

Bevacizumab

Clinical Oncology Departement Assuit University Hospital

Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

the length of time during and after the treatment that a patient lives with the disease but it does not get worse

length of time from the date of diagnosis to the time of death or lost follow up.

the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.

febrile neutropenia/hipoksiya

Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML

Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası